Firazyr (icatibant injection) rapidly eased acute attack symptoms in two Japanese children with hereditary angioedema (HAE), according to a study led by Takeda Pharmaceuticals, its developer. The therapy’s safety and pharmacological profile was also consistent with previous observations of adults and other pediatric patients. Firazyr’s approval in…

Older patients with hereditary angioedema types 1 or 2 can as safely be treated for an acute attack with Firazyr (icatibant) as younger ones, a study found, even though people 65 or older tend to metabolize medicines differently and often are being treated for multiple disorders. The study, “…

Firazyr (icatibant acetate) does not appear to be superior to placebo or symptomatic therapies in treating attacks of angioedema (swelling) caused by angiotensin-converting enzyme (ACE) inhibitors, a pooled analysis of three clinical studies shows. In all trials combined, injections of Firazyr considerably shortened mean time to…

A recently described mutation in the plasminogen (PLG) gene has been reported in an additional family in Germany with hereditary angioedema (HAE), highlighting the importance of raising awareness among clinicians for this rare HAE-causing mutation to ensure correct disease diagnosis and treatment, scientists say. Findings were reported in…

Delays between symptom onset and diagnosis of hereditary angioedema (HAE) types 1 and 2 have been decreasing, according to a real-world study that also revealed a younger age at diagnosis in this patient population over time. The study, “Improvement in diagnostic delays over time in patients…

In rare cases, people with either lymphoma or a non-cancerous blood condition can develop acquired angiodema without hives, a case study reports. The hallmark of the non-cancerous condition, monoclonal gammopathy, is abnormal antibodies in the blood. Hives are red welts on the skin. Angioedema is a condition that normally involves…